Savara (NASDAQ:SVRA) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Wednesday.

A number of other analysts have also commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Savara in a report on Friday, August 10th. Zacks Investment Research lowered shares of Savara from a “hold” rating to a “sell” rating in a report on Thursday, September 13th. Roth Capital initiated coverage on shares of Savara in a report on Monday, August 13th. They set a “neutral” rating and a $12.00 target price for the company. Finally, Canaccord Genuity set a $25.00 target price on shares of Savara and gave the stock a “buy” rating in a report on Tuesday, August 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. Savara currently has an average rating of “Hold” and a consensus price target of $26.80.

SVRA opened at $8.66 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 10.23 and a quick ratio of 10.23. Savara has a 52 week low of $8.41 and a 52 week high of $17.19. The firm has a market cap of $329.86 million, a price-to-earnings ratio of -4.92 and a beta of -0.06.

Savara (NASDAQ:SVRA) last released its earnings results on Wednesday, November 7th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Equities analysts expect that Savara will post -1.42 EPS for the current year.

In other news, CFO David L. Lowrance sold 18,480 shares of the business’s stock in a transaction on Thursday, November 1st. The shares were sold at an average price of $9.22, for a total value of $170,385.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the company. Rhumbline Advisers acquired a new position in shares of Savara in the 2nd quarter valued at $270,000. GSA Capital Partners LLP grew its holdings in shares of Savara by 172.8% in the 2nd quarter. GSA Capital Partners LLP now owns 39,784 shares of the company’s stock valued at $450,000 after buying an additional 25,200 shares during the period. Alps Advisors Inc. grew its holdings in shares of Savara by 39.8% in the 3rd quarter. Alps Advisors Inc. now owns 62,103 shares of the company’s stock valued at $693,000 after buying an additional 17,688 shares during the period. SCP Investment LP acquired a new position in shares of Savara in the 2nd quarter valued at $679,000. Finally, MetLife Investment Advisors LLC acquired a new position in shares of Savara in the 2nd quarter valued at $148,000. 39.20% of the stock is owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Further Reading: Are all No-Load Funds Equal?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Savara (NASDAQ:SVRA)

Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.